Lixte Biotechnology Holdings Inc

LIXT

Company Profile

  • Business description

    Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

  • Contact

    680 East Colorado Boulevard
    Suite 180
    PasadenaCA91101
    USA

    T: +1 631 830-7092

    https://www.lixte.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    4

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,841.908.300.09%
CAC 407,696.2758.28-0.75%
DAX 4023,787.45146.68-0.61%
Dow JONES (US)44,828.53344.110.77%
FTSE 1008,822.910.29-0.00%
HKSE23,916.06153.88-0.64%
NASDAQ20,601.10207.971.02%
Nikkei 22539,810.8824.980.06%
NZX 50 Index12,766.6062.120.49%
S&P 5006,279.3551.930.83%
S&P/ASX 2008,603.007.200.08%
SSE Composite Index3,472.3211.170.32%

Market Movers